Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.53 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 2/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.51 |
| ▸ | CCKBR | P32239 | 4/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24012348 | 1.00 | PSMB8 (0.53) | PSMB8PSMB9PSMB5KLK7KLK5 | |
| SCHEMBL21627105 | 0.93 | CCKBR (0.53) | KLK7KLK5CCKBRRENCTSL | |
| SCHEMBL16862457 | 0.93 | CCKBR (0.53) | KLK7KLK5CCKBRRENCTSL | |
| SCHEMBL19862013 | 0.90 | CTSL (0.54) | PSMB8PSMB9PSMB5KLK7KLK5 | |
| SCHEMBL19861963 | 0.90 | CTSL (0.54) | PSMB8PSMB9PSMB5KLK7KLK5 | |
| SCHEMBL18840120 | 0.90 | CTSL (0.52) | CTSL | |
| SCHEMBL16869898 | 0.89 | MAPT (0.59) | PSMB8PSMB9PSMB5KLK7KLK5 | |
| SCHEMBL16870006 | 0.89 | CTSL (0.51) | CTSL | |
| SCHEMBL21627147 | 0.89 | CTSL (0.51) | CTSL | |
| SCHEMBL17073778 | 0.88 | CTSL (0.64) | PSMB8PSMB9PSMB5KLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160984-B1 | PROCESS FOR PREPARING D-ARGINYL-2,6-DIMETHYL-L-TYROSYL-L-LYSYL-L-PHENYLALANINAMIDE | FLAMMA SPA (IT) | 2021-04-14 | — | — | EP | disclosed |
| US-10696716-B2 | Pharmaceutically relevant aromatic-cationic peptides | STEALTH BIOTHERAPEUTICS CORP (MC) | 2020-06-30 | — | — | US | disclosed |
| US-20200024308-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | STEALTH BIOTHERAPEUTICS CORP (MC) | 2020-01-23 | — | — | US | disclosed |
| US-20170129920-A1 | Process for Preparing D-Arginyl-2,6-Dimethyl-L-Tyrosyl-L-Lysyl-L-Phenylalaninamide | FLAMMA S.P.A. (IT) | 2017-05-11 | — | — | US | disclosed |
| US-20160340389-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2016-11-24 | — | — | US | disclosed |
| WO-2015100376-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | STEALTH PEPTIDES INTERNATIONAL, INC. (MC) | 2015-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340389-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | ADM2, VIP, ANPEP | PSMB8 3803/4885PSMB9 3855/4885PSMB5 4659/4885 |
| US-20200024308-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | ADM2, VIP, ANPEP | PSMB8 3803/4885PSMB9 3855/4885PSMB5 4659/4885 |
| US-10696716-B2 | Pharmaceutically relevant aromatic-cationic peptides | ADM2, VIP, ANPEP | PSMB8 3803/4885PSMB9 3855/4885PSMB5 4659/4885 |
| US-20170129920-A1 | Process for Preparing D-Arginyl-2,6-Dimethyl-L-Tyrosyl-L-Lysyl-L-Phenylalaninamide | ARG2, ARGLU1, GLS | PSMB8 2950/4885PSMB9 2485/4885PSMB5 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.